Tim Knotnerus, Agomab CEO
Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds
Agomab Therapeutics has reeled in $100 million that is set to bankroll the Belgian biotech through a Phase II study in a subset of Crohn …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
